RNA Therapeutics & Manufacturing Asia 2025

RNA Therapeutics & Manufacturing Asia 2025 brings together industry leaders, researchers, and biopharmaceutical innovators to advance Asia’s rapidly growing RNA therapeutics ecosystem. Focused on mRNA, RNA interference (RNAi), and antisense oligonucleotides, the summit explores large-scale RNA synthesis, purification, formulation, and quality control strategies. Sessions will cover scalable, cost-efficient manufacturing technologies and regulatory pathways specific to the Asia-Pacific region.

This technical and strategic meeting provides a platform to tackle challenges in manufacturing high-yield RNA medicines, streamline production pipelines, and foster collaboration among Asian and global stakeholders. The event features case studies from regional innovators and will include opportunities to engage with solution providers offering next-generation LNP platforms, automated purification systems, and process analytics tailored to RNA modalities.

This event is co-located with the World Vaccine Asia Congress - South East Asia 2025.

Participating Companies & Industry Stakeholders:
Expect participation from RNA-focused biopharmaceutical firms, solution providers, and contract manufacturers operating in Asia and internationally. Related events highlight the involvement of companies such as Moderna, Biological E. Limited, Abogen, Aston Sci. in the RNA/vaccines domain.

Speakers from Big Pharma / Industry Experts:

• Felicia Pradera, Director of Regional Research Centre for Respiratory Medicines and Tropical Diseases, Moderna, Australia 
• Ying Bo, CEO, Abogen Biosciences, China
• Poon Hung Fai, CEO, Sirnaomics, China
• Wonil Kim, Chief Scientific Officer, Aston Sci., South Korea
• Dr. Subhash Thuluva, Senior VP & Head-Clinical Development, Biological E. Limited, India